Minerva Neurosciences Submits New Drug Application to FDA fo

WALTHAM, Mass., Aug. 22, 2022 -- Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today... | August 22, 2022

Related Keywords

United States , Helen Shik , Remy Luthringer , Frederick Ahlholm , Minerva Neurosciences , Exchange Commission , Shik Communications , Drug Administration , Minerva Neurosciences Inc , Nasdaq , Globenewswire Inc , New Drug Application , Executive Chairman , Chief Executive , Open Label , Negative Syndrome Scale , Social Performance Scale , Clinical Global Impression , Structured Model Negative , Negative Symptoms Factor Score , Double Blind , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , 022 , Aminerva , Iopharmaceutical , Company , Ocused , N , The , Development , F , Therapies , O , Treat , Central , Nervous , Ystem Nerv Us6033802058 ,